

**AB0561 B CELL THERAPY IN REFRACTORY/ RELAPSED ANCA ASSOCIATED VASCULITIS- A SINGLE CENTRE PROSPECTIVE OBSERVATIONAL STUDY**

G.G. Ekbote, R. Gupta, N. Mendiratta, N. Negalur, M. Bindroo, V. Singal. *Rheumatology, MEDANTA, the Medicity, Gurgaon, India*

**Background:** Rituximab (Rtx), a novel biological, having B cell depletion mechanism is an anti- CD 20 antibody and is found to be useful in patients of ANCA associated vasculitis. In AAV the disease activity correlates with increased circulating B cells. Rituximab has been found to be useful in depleting these B cells. According to the RAVE study, Rituximab was shown to be non-inferior to Cyclophosphamide in inducing remission. It also showed that the regimen (Rtx) may be superior to the standard regimen of Cyclophosphamide and glucocorticoids for remission induction in severe relapsing ANCA-associated vasculitis.

In our study, B cell therapy was given in those patients only who had persistent disease activity or relapse.

**Objectives:** To assess response of Rtx in relapsed /refractory cases of AAV and show that it is a good therapeutic strategy in such cases.

**Methods:** In our cohort there were 49 patients of ANCA associated vasculitis, diagnosed by clinical and serological criteria, (by both ELISA and IFA) classified according to ACR criteria and supported, wherever possible, by biopsy. In this prospective study, patients were seen during January 2012 to January 2017. A total of 15 patients received Rituximab for various reasons. Rituximab (Rtx) was given as 1 gram infusion on day 1 and day 15 as induction therapy and subsequently 6 monthly maintenance doses of 500 mg were administered. No other immunosuppression other than steroids were given.

**Results:** Median follow up was 22 months. All patients had received Cyclophosphamide (median dose 6 grams) and 1mg/kg glucocorticoids at onset. Among the patients who received Rituximab, all had anti PR3 antibody positive & all were GPA clinically. 14 patients (93.33%) had lung involvement, renal involvement was seen in 7 (46.6%) patients, 13 (86.6%) patients had upper respiratory tract involvement, 6 (40%) had ophthalmic involvement. Nervous system involvement was seen in 5 (33.3%) and myocarditis was seen in 3 (20%) each. 3 (20%) patients had gangrene.

Indications for receiving Rtx were heterogenous. It was given for involvement of lung, renal, ophthalmic, upper respiratory and nervous system in 6 (40%), 3 (20%), 3 (20%), 1 (6.66%) and 1 (6.66%) respectively. Whereas 1 (6.66%) patient received Rtx for persistent disease activity.

12 out of 15 patients (80%) achieved remission at mean follow up of 3 months while one achieved at 6 months follow up & all maintained continued remission. 1 patient was due for 3-month follow up. 1 patient died due to lung infection during the course. 4 patients had permanent morbidities/organ damage which they already had before starting Rtx. Only one patient had infusion reaction at the end of 1st induction however she remained in remission after the first dose itself.

**Conclusions:** 86.6% patients achieved remission after Rtx and remained in continuous remission at median follow up of 22 months. Rtx is a very good therapeutic strategy for refractory/relapsed especially PR3+ AAV also it can be used as a maintenance regimen for long term.

**References:**

[1] Stone JH, Merkel PA, Spiera R, Seo et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. *N Engl J Med.* 2010;363:221–23.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2017-eular.5596

**AB0562 CLASSIFICATION OF ANCA ASSOCIATED VASCULITIS BASED ON PR3 AND MPO SEROLOGY & THEIR OUTCOME: A SINGLE CENTRE PROSPECTIVE STUDY**

G.G. Ekbote, R. Gupta, N. Mendiratta, N. Negalur, M. Bindroo, V. Singal. *Rheumatology, MEDANTA, the Medicity, Gurgaon, India*

**Background:** It is often difficult to classify small vessel vasculitis, especially AAV, as Granulomatosis polyangiitis [GPA], Microscopic polyangiitis [MPA], Eosinophilic granulomatosis polyangiitis [EGPA] & Idiopathic crescentic glomerulonephritis. But with the discovery of ANCA, rheumatologists divide this as ANCA positive or negative vasculitis.

**Objectives:** To classify AAV as anti-proteinase 3 (PR3) antibody+ or anti-myeloperoxidase (MPO) antibody + & compare their clinical presentation & outcome.

**Methods:** 49 patients were included in our study from August 2011 till January 2017. Patients were classified according to PR3 and MPO serology [based on ELISA].

**Results:** Median follow up was 18 months. PR3 + were 38 and 11 patients were MPO-. GPA was significantly higher in PR3 Group vs MPO group [36 (94.7%) vs 1 (9.1%) p<0.0001\*] while MPA was significantly lower in PR3 group as compared to MPO [2 [5.3%] vs 5 [45.45%] p=0.001\*]. All EGPA were MP0+ (4 [36.35%]). 48 fulfilled ACR clinical criteria for GPA/MPA or EGPA. 1 patient with arteritic anterior ischemic optic neuropathy without any other major organ involvement had significantly higher titres of MPO antibodies & was sorted as unclassified AAV. None were idiopathic crescentic glomerulonephritis in our cohort. 18 were biopsy proven [15 PR3+vs 3 MPO+]. Lung involvement was significantly higher in PR3 group than MPO group [32 [84.2%] vs 6 [54.5%] p=0.037\*]. Kidney involvement

was also more in PR3 group but was not statistically significant [20 [52.6%] vs 4 [36.4%] p=0.341]. Upper respiratory involvement was significantly higher in PR3 group [26 [68.4%] vs 3 [27.3%] p=0.014\*].

Comparison between manifestations of ophthalmic, cardiac, peripheral vascular system & nervous systems of PR3+ & MPO+ groups was not statistically significant.

Complete remission without permanent organ damage was seen in 16 (42%) vs 6 (54.5%) in PR3 and MPO groups respectively (p=0.465). Frequency of relapse/refractory disease, though higher in PR3 group, was not statistically significant (PR3 vs MPO, 10 [26.3%] vs 1 [9.1%] p=0.228). Rates of morbidity & mortality were not significant statistically between PR3 & MPO groups (11 [28.9%] vs 2 [18.2%] p=0.476 & 3 [7.9%] vs 1 [9.1%] p=0.899 respectively). Similar comparisons were made between those who were classified clinically as GPA, MPA & EGPA with respect to remission, relapse, morbidity and mortality. All EGPA achieved remission. Comparison between groups when divided as GPA & PR3 and MPA & MPO did not show statistical significance. 15 patients (all clinically GPA & PR3+) of the cohort [39.5%] received rituximab for relapse/refractory disease during/after initial induction therapy with cyclophosphamide & steroids.

**Conclusions:** In this study, we did not find any advantage of clinical classification over serological. Wrongly diagnosing patients when disease is still evolving & inter-clinician bias are eliminated when classifying patients according to serology. Classification as PR3 & MPO is simpler and universal.

**References:**

[1] Hunder, G. G. et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. *Introduction. Arthritis Rheum.* 33,1065–1067 (1990).

[2] Houben E, Bax WA, van Dam B, et al. Diagnosing ANCA-associated vasculitis in ANCA positive patients: A retrospective analysis on the role of clinical symptoms and the ANCA titre. *Carubbi. F, ed. Medicine.* 2016;95(40):e5096.

**Disclosure of Interest:** None declared

**DOI:** 10.1136/annrheumdis-2017-eular.4878

**AB0563 RITUXIMAB IN PATIENTS WITH TAKAYASU ARTERITIS: A SEVEN PATIENTS EXPERIENCE**

G. Pazzola<sup>1</sup>, F. Muratore<sup>1</sup>, N. Pipitone<sup>1</sup>, F. Crescentini<sup>1</sup>, P. Cacoub<sup>2</sup>, L. Boiardi<sup>1</sup>, L. Spaggiari<sup>3</sup>, C. Comarmond<sup>2</sup>, S. Croci<sup>4</sup>, D. Saadoun<sup>2</sup>, C. Salvarani<sup>1</sup>. <sup>1</sup>Rheumatology, Arcispedale S Maria Nuova, Reggio Emilia, Italy; <sup>2</sup>Internal Medicine and Clinical Immunology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France; <sup>3</sup>Radiology; <sup>4</sup>Inflammation Laboratory, Clinical Immunology, Allergy and Advanced Biotechnologies Unit, Arcispedale S Maria Nuova, Reggio Emilia, Italy

**Background:** Takayasu arteritis (TAK) is a large vessel vasculitis involving the aorta and its major branches in patients younger than 40 years. Glucocorticoids (GCs) are the mainstay of treatment for TAK, but relapses and GC dependence are seen in more than two-thirds of patients. Increasing evidence supports a role for B cells in the pathogenesis of TAK. Circulating plasmablasts and memory B cells are increased, while naive B cells are decreased in patients with active TAK as compared with inactive and control patients [1]. These findings suggest a potential role for B cell depleting therapy in TAK.

**Objectives:** Our aim was to assess the efficacy and safety of Rituximab (RTX) in a series of 7 patients with TAK.

**Methods:** We conducted an open-label study on 7 TAK patients (5 followed prospectively, 2 retrospective cases) treated with RTX. All patients satisfied the American college of Rheumatology classification criteria for TAK. Six of the 7 patients had a disease refractory to high dose GCs and conventional immunosuppressive (IS) and/or biologic agents. One newly diagnosed, treatment naïve TAK patient refused GCs and received RTX alone. RTX was administered according to rheumatoid arthritis scheme (2 infusions of 1.000 mg, 15 days apart). Clinical evaluation, laboratory tests (full blood count, ESR, CRP) and imaging modalities (CTA or MRA, and PET/CT) were performed at first RTX administration and every 6 months thereafter. Disease activity was assessed using Kerr index. Radiographic disease progression was defined as new or worsening lesions at follow-up CTA or MRA. PET/CT was considered positive for active disease if two or more large vessels showed grade 2 FDG uptake or higher.

**Results:** Seven patients (6 females) were included in the study. Mean (SD) age was 32.4 (±16.1) years. At first RTX administration, all patients had active disease

Table 1. Parameters of disease activity before and after Rituximab treatment

Case	Age/Sex	Disease duration (yr)	Previous therapy	ESR CRP at first RTX (mg/dL)	PDN dose at first RTX (mg/day)	Corticosteroid IS therapy	RTX (mg/kg)	ESR CRP 6 weeks after first RTX (mg/dL)	ESR CRP 6 months after first RTX (mg/dL)	ESR CRP 12 months after first RTX (mg/dL)	ESR CRP 24 months after first RTX (mg/dL)	ESR CRP 36 months after first RTX (mg/dL)	ESR CRP 48 months after first RTX (mg/dL)	ESR CRP 60 months after first RTX (mg/dL)	ESR CRP 72 months after first RTX (mg/dL)	ESR CRP 84 months after first RTX (mg/dL)	ESR CRP 96 months after first RTX (mg/dL)	ESR CRP 108 months after first RTX (mg/dL)	ESR CRP 120 months after first RTX (mg/dL)	ESR CRP 132 months after first RTX (mg/dL)	ESR CRP 144 months after first RTX (mg/dL)	ESR CRP 156 months after first RTX (mg/dL)	ESR CRP 168 months after first RTX (mg/dL)	ESR CRP 180 months after first RTX (mg/dL)	ESR CRP 192 months after first RTX (mg/dL)	ESR CRP 204 months after first RTX (mg/dL)	ESR CRP 216 months after first RTX (mg/dL)	ESR CRP 228 months after first RTX (mg/dL)	ESR CRP 240 months after first RTX (mg/dL)	ESR CRP 252 months after first RTX (mg/dL)	ESR CRP 264 months after first RTX (mg/dL)	ESR CRP 276 months after first RTX (mg/dL)	ESR CRP 288 months after first RTX (mg/dL)	ESR CRP 300 months after first RTX (mg/dL)	ESR CRP 312 months after first RTX (mg/dL)	ESR CRP 324 months after first RTX (mg/dL)	ESR CRP 336 months after first RTX (mg/dL)	ESR CRP 348 months after first RTX (mg/dL)	ESR CRP 360 months after first RTX (mg/dL)	ESR CRP 372 months after first RTX (mg/dL)	ESR CRP 384 months after first RTX (mg/dL)	ESR CRP 396 months after first RTX (mg/dL)	ESR CRP 408 months after first RTX (mg/dL)	ESR CRP 420 months after first RTX (mg/dL)	ESR CRP 432 months after first RTX (mg/dL)	ESR CRP 444 months after first RTX (mg/dL)	ESR CRP 456 months after first RTX (mg/dL)	ESR CRP 468 months after first RTX (mg/dL)	ESR CRP 480 months after first RTX (mg/dL)	ESR CRP 492 months after first RTX (mg/dL)	ESR CRP 504 months after first RTX (mg/dL)	ESR CRP 516 months after first RTX (mg/dL)	ESR CRP 528 months after first RTX (mg/dL)	ESR CRP 540 months after first RTX (mg/dL)	ESR CRP 552 months after first RTX (mg/dL)	ESR CRP 564 months after first RTX (mg/dL)	ESR CRP 576 months after first RTX (mg/dL)	ESR CRP 588 months after first RTX (mg/dL)	ESR CRP 600 months after first RTX (mg/dL)	ESR CRP 612 months after first RTX (mg/dL)	ESR CRP 624 months after first RTX (mg/dL)	ESR CRP 636 months after first RTX (mg/dL)	ESR CRP 648 months after first RTX (mg/dL)	ESR CRP 660 months after first RTX (mg/dL)	ESR CRP 672 months after first RTX (mg/dL)	ESR CRP 684 months after first RTX (mg/dL)	ESR CRP 696 months after first RTX (mg/dL)	ESR CRP 708 months after first RTX (mg/dL)	ESR CRP 720 months after first RTX (mg/dL)	ESR CRP 732 months after first RTX (mg/dL)	ESR CRP 744 months after first RTX (mg/dL)	ESR CRP 756 months after first RTX (mg/dL)	ESR CRP 768 months after first RTX (mg/dL)	ESR CRP 780 months after first RTX (mg/dL)	ESR CRP 792 months after first RTX (mg/dL)	ESR CRP 804 months after first RTX (mg/dL)	ESR CRP 816 months after first RTX (mg/dL)	ESR CRP 828 months after first RTX (mg/dL)	ESR CRP 840 months after first RTX (mg/dL)	ESR CRP 852 months after first RTX (mg/dL)	ESR CRP 864 months after first RTX (mg/dL)	ESR CRP 876 months after first RTX (mg/dL)	ESR CRP 888 months after first RTX (mg/dL)	ESR CRP 900 months after first RTX (mg/dL)	ESR CRP 912 months after first RTX (mg/dL)	ESR CRP 924 months after first RTX (mg/dL)	ESR CRP 936 months after first RTX (mg/dL)	ESR CRP 948 months after first RTX (mg/dL)	ESR CRP 960 months after first RTX (mg/dL)	ESR CRP 972 months after first RTX (mg/dL)	ESR CRP 984 months after first RTX (mg/dL)	ESR CRP 996 months after first RTX (mg/dL)	ESR CRP 1008 months after first RTX (mg/dL)	ESR CRP 1020 months after first RTX (mg/dL)	ESR CRP 1032 months after first RTX (mg/dL)	ESR CRP 1044 months after first RTX (mg/dL)	ESR CRP 1056 months after first RTX (mg/dL)	ESR CRP 1068 months after first RTX (mg/dL)	ESR CRP 1080 months after first RTX (mg/dL)	ESR CRP 1092 months after first RTX (mg/dL)	ESR CRP 1104 months after first RTX (mg/dL)	ESR CRP 1116 months after first RTX (mg/dL)	ESR CRP 1128 months after first RTX (mg/dL)	ESR CRP 1140 months after first RTX (mg/dL)	ESR CRP 1152 months after first RTX (mg/dL)	ESR CRP 1164 months after first RTX (mg/dL)	ESR CRP 1176 months after first RTX (mg/dL)	ESR CRP 1188 months after first RTX (mg/dL)	ESR CRP 1200 months after first RTX (mg/dL)	ESR CRP 1212 months after first RTX (mg/dL)	ESR CRP 1224 months after first RTX (mg/dL)	ESR CRP 1236 months after first RTX (mg/dL)	ESR CRP 1248 months after first RTX (mg/dL)	ESR CRP 1260 months after first RTX (mg/dL)	ESR CRP 1272 months after first RTX (mg/dL)	ESR CRP 1284 months after first RTX (mg/dL)	ESR CRP 1296 months after first RTX (mg/dL)	ESR CRP 1308 months after first RTX (mg/dL)	ESR CRP 1320 months after first RTX (mg/dL)	ESR CRP 1332 months after first RTX (mg/dL)	ESR CRP 1344 months after first RTX (mg/dL)	ESR CRP 1356 months after first RTX (mg/dL)	ESR CRP 1368 months after first RTX (mg/dL)	ESR CRP 1380 months after first RTX (mg/dL)	ESR CRP 1392 months after first RTX (mg/dL)	ESR CRP 1404 months after first RTX (mg/dL)	ESR CRP 1416 months after first RTX (mg/dL)	ESR CRP 1428 months after first RTX (mg/dL)	ESR CRP 1440 months after first RTX (mg/dL)	ESR CRP 1452 months after first RTX (mg/dL)	ESR CRP 1464 months after first RTX (mg/dL)	ESR CRP 1476 months after first RTX (mg/dL)	ESR CRP 1488 months after first RTX (mg/dL)	ESR CRP 1500 months after first RTX (mg/dL)	ESR CRP 1512 months after first RTX (mg/dL)	ESR CRP 1524 months after first RTX (mg/dL)	ESR CRP 1536 months after first RTX (mg/dL)	ESR CRP 1548 months after first RTX (mg/dL)	ESR CRP 1560 months after first RTX (mg/dL)	ESR CRP 1572 months after first RTX (mg/dL)	ESR CRP 1584 months after first RTX (mg/dL)	ESR CRP 1596 months after first RTX (mg/dL)	ESR CRP 1608 months after first RTX (mg/dL)	ESR CRP 1620 months after first RTX (mg/dL)	ESR CRP 1632 months after first RTX (mg/dL)	ESR CRP 1644 months after first RTX (mg/dL)	ESR CRP 1656 months after first RTX (mg/dL)	ESR CRP 1668 months after first RTX (mg/dL)	ESR CRP 1680 months after first RTX (mg/dL)	ESR CRP 1692 months after first RTX (mg/dL)	ESR CRP 1704 months after first RTX (mg/dL)	ESR CRP 1716 months after first RTX (mg/dL)	ESR CRP 1728 months after first RTX (mg/dL)	ESR CRP 1740 months after first RTX (mg/dL)	ESR CRP 1752 months after first RTX (mg/dL)	ESR CRP 1764 months after first RTX (mg/dL)	ESR CRP 1776 months after first RTX (mg/dL)	ESR CRP 1788 months after first RTX (mg/dL)	ESR CRP 1800 months after first RTX (mg/dL)	ESR CRP 1812 months after first RTX (mg/dL)	ESR CRP 1824 months after first RTX (mg/dL)	ESR CRP 1836 months after first RTX (mg/dL)	ESR CRP 1848 months after first RTX (mg/dL)	ESR CRP 1860 months after first RTX (mg/dL)	ESR CRP 1872 months after first RTX (mg/dL)	ESR CRP 1884 months after first RTX (mg/dL)	ESR CRP 1896 months after first RTX (mg/dL)	ESR CRP 1908 months after first RTX (mg/dL)	ESR CRP 1920 months after first RTX (mg/dL)	ESR CRP 1932 months after first RTX (mg/dL)	ESR CRP 1944 months after first RTX (mg/dL)	ESR CRP 1956 months after first RTX (mg/dL)	ESR CRP 1968 months after first RTX (mg/dL)	ESR CRP 1980 months after first RTX (mg/dL)	ESR CRP 1992 months after first RTX (mg/dL)	ESR CRP 2004 months after first RTX (mg/dL)	ESR CRP 2016 months after first RTX (mg/dL)	ESR CRP 2028 months after first RTX (mg/dL)	ESR CRP 2040 months after first RTX (mg/dL)	ESR CRP 2052 months after first RTX (mg/dL)	ESR CRP 2064 months after first RTX (mg/dL)	ESR CRP 2076 months after first RTX (mg/dL)	ESR CRP 2088 months after first RTX (mg/dL)	ESR CRP 2100 months after first RTX (mg/dL)	ESR CRP 2112 months after first RTX (mg/dL)	ESR CRP 2124 months after first RTX (mg/dL)	ESR CRP 2136 months after first RTX (mg/dL)	ESR CRP 2148 months after first RTX (mg/dL)	ESR CRP 2160 months after first RTX (mg/dL)	ESR CRP 2172 months after first RTX (mg/dL)	ESR CRP 2184 months after first RTX (mg/dL)	ESR CRP 2196 months after first RTX (mg/dL)	ESR CRP 2208 months after first RTX (mg/dL)	ESR CRP 2220 months after first RTX (mg/dL)	ESR CRP 2232 months after first RTX (mg/dL)	ESR CRP 2244 months after first RTX (mg/dL)	ESR CRP 2256 months after first RTX (mg/dL)	ESR CRP 2268 months after first RTX (mg/dL)	ESR CRP 2280 months after first RTX (mg/dL)	ESR CRP 2292 months after first RTX (mg/dL)	ESR CRP 2304 months after first RTX (mg/dL)	ESR CRP 2316 months after first RTX (mg/dL)	ESR CRP 2328 months after first RTX (mg/dL)	ESR CRP 2340 months after first RTX (mg/dL)	ESR CRP 2352 months after first RTX (mg/dL)	ESR CRP 2364 months after first RTX (mg/dL)	ESR CRP 2376 months after first RTX (mg/dL)	ESR CRP 2388 months after first RTX (mg/dL)	ESR CRP 2400 months after first RTX (mg/dL)	ESR CRP 2412 months after first RTX (mg/dL)	ESR CRP 2424 months after first RTX (mg/dL)	ESR CRP 2436 months after first RTX (mg/dL)	ESR CRP 2448 months after first RTX (mg/dL)	ESR CRP 2460 months after first RTX (mg/dL)	ESR CRP 2472 months after first RTX (mg/dL)	ESR CRP 2484 months after first RTX (mg/dL)	ESR CRP 2496 months after first RTX (mg/dL)	ESR CRP 2508 months after first RTX (mg/dL)	ESR CRP 2520 months after first RTX (mg/dL)	ESR CRP 2532 months after first RTX (mg/dL)	ESR CRP 2544 months after first RTX (mg/dL)	ESR CRP 2556 months after first RTX (mg/dL)	ESR CRP 2568 months after first RTX (mg/dL)	ESR CRP 2580 months after first RTX (mg/dL)	ESR CRP 2592 months after first RTX (mg/dL)	ESR CRP 2604 months after first RTX (mg/dL)	ESR CRP 2616 months after first RTX (mg/dL)	ESR CRP 2628 months after first RTX (mg/dL)	ESR CRP 2640 months after first RTX (mg/dL)	ESR CRP 2652 months after first RTX (mg/dL)	ESR CRP 2664 months after first RTX (mg/dL)	ESR CRP 2676 months after first RTX (mg/dL)	ESR CRP 2688 months after first RTX (mg/dL)	ESR CRP 2700 months after first RTX (mg/dL)	ESR CRP 2712 months after first RTX (mg/dL)	ESR CRP 2724 months after first RTX (mg/dL)	ESR CRP 2736 months after first RTX (mg/dL)	ESR CRP 2748 months after first RTX (mg/dL)	ESR CRP 2760 months after first RTX (mg/dL)	ESR CRP 2772 months after first RTX (mg/dL)	ESR CRP 2784 months after first RTX (mg/dL)	ESR CRP 2796 months after first RTX (mg/dL)	ESR CRP 2808 months after first RTX (mg/dL)	ESR CRP 2820 months after first RTX (mg/dL)	ESR CRP 2832 months after first RTX (mg/dL)	ESR CRP 2844 months after first RTX (mg/dL)	ESR CRP 2856 months after first RTX (mg/dL)	ESR CRP 2868 months after first RTX (mg/dL)	ESR CRP 2880 months after first RTX (mg/dL)	ESR CRP 2892 months after first RTX (mg/dL)	ESR CRP 2904 months after first RTX (mg/dL)	ESR CRP 2916 months after first RTX (mg/dL)	ESR CRP 2928 months after first RTX (mg/dL)	ESR CRP 2940 months after first RTX (mg/dL)	ESR CRP 2952 months after first RTX (mg/dL)	ESR CRP 2964 months after first RTX (mg/dL)	ESR CRP 2976 months after first RTX (mg/dL)	ESR CRP 2988 months after first RTX (mg/dL)	ESR CRP 3000 months after first RTX (mg/dL)	ESR CRP 3012 months after first RTX (mg/dL)	ESR CRP 3024 months after first RTX (mg/dL)	ESR CRP 3036 months after first RTX (mg/dL)	ESR CRP 3048 months after first RTX (mg/dL)	ESR CRP 3060 months after first RTX (mg/dL)	ESR CRP 3072 months after first RTX (mg/dL)	ESR CRP 3084 months after first RTX (mg/dL)	ESR CRP 3096 months after first RTX (mg/dL)	ESR CRP 3108 months after first RTX (mg/dL)	ESR CRP 3120 months after first RTX (mg/dL)	ESR CRP 3132 months after first RTX (mg/dL)	ESR CRP 3144 months after first RTX (mg/dL)	ESR CRP 3156 months after first RTX (mg/dL)	ESR CRP 3168 months after first RTX (mg/dL)	ESR CRP 3180 months after first RTX (mg/dL)	ESR CRP 3192 months after first RTX (mg/dL)	ESR CRP 3204 months after first RTX (mg/dL)	ESR CRP 3216 months after first RTX (mg/dL)	ESR CRP 3228 months after first RTX (mg/dL)	ESR CRP 3240 months after first RTX (mg/dL)	ESR CRP 3252 months after first RTX (mg/dL)	ESR CRP 3264 months after first RTX (mg/dL)	ESR CRP 3276 months after first RTX (mg/dL)	ESR CRP 3288 months after first RTX (mg/dL)	ESR CRP 3300 months after first RTX (mg/dL)	ESR CRP 3312 months after first RTX (mg/dL)	ESR CRP 3324 months after first RTX (mg/dL)	ESR CRP 3336 months after first RTX (mg/dL)	ESR CRP 3348 months after first RTX (mg/dL)	ESR CRP 3360 months after first RTX (mg/dL)	ESR CRP 3372 months after first RTX (mg/dL)	ESR CRP 3384 months after first RTX (mg/dL)	ESR CRP 3396 months after first RTX (mg/dL)	ESR CRP 3408 months after first RTX (mg/dL)	ESR CRP 3420 months after first RTX (mg/dL)	ESR CRP 3432 months after first RTX (mg/dL)	ESR CRP 3444 months after first RTX (mg/dL)	ESR CRP 3456 months after first RTX (mg/dL)	ESR CRP 3468 months after first RTX (mg/dL)	ESR CRP 3480 months after first RTX (mg/dL)	ESR CRP 3492 months after first RTX (mg/dL)	ESR CRP 3504 months after first RTX (mg/dL)	ESR CRP 3516 months after first RTX (mg/dL)	ESR CRP 3528 months after first RTX (mg/dL)	ESR CRP 3540 months after first RTX (mg/dL)	ESR CRP 3552 months after first RTX (mg/dL)	ESR CRP 3564 months after first RTX (mg/dL)	ESR CRP 3576 months after first RTX (mg/dL)	ESR CRP 3588 months after first RTX (mg/dL)	ESR CRP 3600 months after first RTX (mg/dL)	ESR CRP 3612 months after first RTX (mg/dL)	ESR CRP 3624 months after first RTX (mg/dL)	ESR CRP 3636 months after first RTX (mg/dL)	ESR CRP 3648 months after first RTX (mg/dL)	ESR CRP 3660 months after first RTX (mg/dL)	ESR CRP 3672 months after first RTX (mg/dL)	ESR CRP 3684 months after first RTX (mg/dL)	ESR CRP 3696 months after first RTX (mg/dL)	ESR CRP 3708 months after first RTX (mg/dL)	ESR CRP 3720 months after first RTX (mg/dL)	ESR CRP 3732 months after first RTX (mg/dL)	ESR CRP 3744 months after first RTX (mg/dL)	ESR CRP 3756 months after first RTX (mg/dL)	ESR CRP 3768 months after first RTX (mg/dL)	ESR CRP 3780 months after first RTX (mg/dL)	ESR CRP 3792 months after first RTX (mg/dL)	ESR CRP 3804 months after first RTX (mg/dL)	ESR CRP 3816 months after first RTX (mg/dL)	ESR CRP 3828 months after first RTX (mg/dL)	ESR CRP 3840 months after first RTX (mg/dL)	ESR CRP 3852 months after first RTX (mg/dL)	ESR CRP 3864 months after first RTX (mg/dL)	ESR CRP 3876 months after first RTX (mg/dL)	ESR CRP 3888 months after first RTX (mg/dL)	ESR CRP 3900 months after first RTX (mg/dL)	ESR CRP 3912 months after first RTX (mg/dL)	ESR CRP 3924 months after first RTX (mg/dL)	ESR CRP 3936 months after first RTX (mg/dL)	ESR CRP 3948 months after first RTX (mg/dL)	ESR CRP 3960 months after first RTX (mg/dL)	ESR CRP 3972 months after first RTX (mg/dL)	ESR CRP 3984 months after first RTX (mg/dL)	ESR CRP 3996 months after first RTX (mg/dL)	ESR CRP 4008 months after first RTX (mg/dL)	ESR CRP 4020 months after first RTX (mg/dL)	ESR CRP 4032 months after first RTX (mg/dL)	ESR CRP 4044 months after first RTX (mg/dL)	ESR CRP 4056 months after first RTX (mg/dL)	ESR CRP 4068 months after first RTX (mg/dL)	ESR CRP 4080 months after first RTX (mg/dL)	ESR CRP 4092 months after first RTX (mg/dL)	ESR CRP 4104 months after first RTX (mg/dL)	ESR CRP 4116 months after first RTX (mg/dL)	ESR CRP 4128 months after first RTX (mg/dL)	ESR CRP 4140 months after first RTX (mg/dL)	ESR CRP 4152 months after first RTX (mg/dL)	ESR CRP 4164 months after first RTX (mg/dL)	ESR CRP 4176 months after first RTX (mg/dL)	ESR
------	---------	-----------------------	------------------	------------------------------	--------------------------------	---------------------------	-------------	---	--	---	---	---	---	---	---	---	---	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	---	-----